维多珠单抗与托法替布联合治疗一名溃疡性结肠炎合并脊柱关节炎患者 - Suppr

Suppr

超能文献

Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.

作者信息

Le Berre Catherine, Loeuille Damien, Peyrin-Biroulet Laurent

机构信息

Institut des Maladies de l'Appareil Digestif, Nantes University Hospital, Nantes, France.

Department of Rheumatology, Nancy University Hospital, Nancy, Université de Lorraine, France.

出版信息

Clin Gastroenterol Hepatol. 2019 Mar;17(4):794-796. doi: 10.1016/j.cgh.2018.08.017. Epub 2018 Aug 13.

DOI:10.1016/j.cgh.2018.08.017

PMID:30114486

Abstract

摘要

相似文献

Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.维多珠单抗与托法替布联合治疗一名溃疡性结肠炎合并脊柱关节炎患者

Clin Gastroenterol Hepatol. 2019 Mar;17(4):794-796. doi: 10.1016/j.cgh.2018.08.017. Epub 2018 Aug 13.

Efficacy of tofacitinib treatment in ulcerative colitis.托法替布治疗溃疡性结肠炎的疗效。

Gastroenterol Hepatol. 2019 Jun-Jul;42(6):403-412. doi: 10.1016/j.gastrohep.2019.03.002. Epub 2019 May 14.

Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?社论：托法替布与生物制剂治疗中重度溃疡性结肠炎——哪一种是同类最佳？

Aliment Pharmacol Ther. 2018 Feb;47(4):539-540. doi: 10.1111/apt.14480.

Treatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis With Vedolizumab and Tofacitinib.维多珠单抗和托法替布治疗溃疡性结肠炎和血清阴性炎性脊柱关节炎

Inflamm Bowel Dis. 2020 Oct 23;26(11):e146. doi: 10.1093/ibd/izaa158.

Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.社论：托法替布与生物制剂治疗中重度溃疡性结肠炎——哪一种堪称同类最佳？作者回复。

Aliment Pharmacol Ther. 2018 Feb;47(4):540-541. doi: 10.1111/apt.14486.

Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.系统评价与网络荟萃分析：中重度溃疡性结肠炎的医学干预措施对健康相关生活质量的影响。

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1174-1185. doi: 10.1111/apt.15005. Epub 2018 Oct 30.

Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.系统评价与网络荟萃分析：托法替布与生物疗法治疗中重度溃疡性结肠炎的比较评估。

Aliment Pharmacol Ther. 2018 Feb;47(4):454-465. doi: 10.1111/apt.14449. Epub 2017 Dec 4.

Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.中重度溃疡性结肠炎治疗策略的成本-效果分析。

Inflamm Bowel Dis. 2018 Oct 12;24(11):2291-2302. doi: 10.1093/ibd/izy114.

[Emerging Therapies: What Are Promising in the Near Future?].新兴疗法：近期有哪些前景可期的疗法？

Korean J Gastroenterol. 2018 Feb 25;71(2):81-88. doi: 10.4166/kjg.2018.71.2.81.

Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia.信：托法替布治疗生物制剂治疗失败的溃疡性结肠炎——澳大利亚单中心真实世界经验

Aliment Pharmacol Ther. 2021 Aug;54(4):532-533. doi: 10.1111/apt.16468.

引用本文的文献

Real-world Effectiveness of Tofacitinib on Ulcerative Colitis-Associated Spondyloarthropathy: a multicenter prospective study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).托法替布治疗溃疡性结肠炎相关性脊柱关节炎的真实世界疗效：来自意大利炎症性肠病研究组（IG-IBD）的多中心前瞻性研究。

Therap Adv Gastroenterol. 2025 Aug 25;18:17562848251367559. doi: 10.1177/17562848251367559. eCollection 2025.

Dual anti-cytokine biologic and/or targeted synthetic therapy combination in spondyloarthritis: a narrative review. Are we missing the opportunity for higher remission rates?脊柱关节炎中双重抗细胞因子生物制剂和/或靶向合成疗法联合应用：一项叙述性综述。我们是否错失了实现更高缓解率的机会？

Front Med (Lausanne). 2025 Jun 3;12:1576411. doi: 10.3389/fmed.2025.1576411. eCollection 2025.

Ferroptosis: a new mechanism of traditional Chinese medicine for treating ulcerative colitis.铁死亡：中医治疗溃疡性结肠炎的新机制

Front Pharmacol. 2024 Jun 4;15:1379058. doi: 10.3389/fphar.2024.1379058. eCollection 2024.

Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain.双靶向治疗银屑病关节炎和脊柱关节炎患者：来自西班牙的真实世界多中心经验。

Front Immunol. 2023 Oct 23;14:1283251. doi: 10.3389/fimmu.2023.1283251. eCollection 2023.

Advanced Combination Treatment With Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease.生物制剂与新型小分子药物联合用于炎症性肠病的先进治疗方案

Gastroenterol Hepatol (N Y). 2023 May;19(5):251-263.

Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease.双重生物疗法在炎症性肠病治疗中的新作用。

World J Clin Cases. 2023 Apr 26;11(12):2621-2630. doi: 10.12998/wjcc.v11.i12.2621.

Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports.托法替布治疗炎症性肠病相关关节炎：两例病例报告。

J Med Case Rep. 2023 Mar 1;17(1):71. doi: 10.1186/s13256-023-03796-2.

Identification of potential immunomodulators from Pulsatilla decoction that act on therapeutic targets for ulcerative colitis based on pharmacological activity, absorbed ingredients, and in-silico molecular docking.基于药理活性、吸收成分和计算机模拟分子对接，从白头翁汤中鉴定作用于溃疡性结肠炎治疗靶点的潜在免疫调节剂。

Chin Med. 2022 Nov 24;17(1):132. doi: 10.1186/s13020-022-00684-7.

Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology.炎症性肠病相关脊柱关节炎：风湿病学中最后一个未被探索的领域。

Mediterr J Rheumatol. 2022 Apr 15;33(Suppl 1):126-136. doi: 10.31138/mjr.33.1.126. eCollection 2022 Mar.

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study.联合生物制剂或小分子药物治疗炎症性肠病或免疫介导的炎症性疾病的安全性和疗效：一项欧洲回顾性观察研究。

United European Gastroenterol J. 2021 Dec;9(10):1136-1147. doi: 10.1002/ueg2.12170. Epub 2021 Oct 25.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验